Citi opens ‘positive catalyst watch’ on Edwards Lifesciences

Citi opens a “90-day positive catalyst watch” on shares of Edwards Lifesciences while keeping a Buy rating on the shares with an $83 price target heading into the Transcatheter Cardiovascular Therapeutics Conference. Citi does not expect an outsized stock move in response to the data itself, but with the stock still down 20% from its pre-earnings price, it expects the shares to trade higher from now into the conference as investors continue to digest the Q2 results and optimism around its Transcatheter Mitral and Tricuspid Therapies portfolio resumes.